CAREFIRST COMMERCIAL - NON-RISK - SPC

This fax machine is located in a secure location as required by HIPAA regulations. Fax complete signed and dated forms to CVS Caremark at 866-249-6155. Please contact CVS Caremark at 866-814-5506 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of the medication.

Patier	nt Information			
Patien	t Name:			
Patien	t Phone:			
Patien	t ID:			
Patien	t Group:			
Patien	t DOB: / / / / / / / / / / / / / / / / / / /			
Physi	cian Information			
Physic	cian Name			
Physic	cian Phone:			
Physic	cian Fax:			
Physic	cian Addr.:			
City, S	t, Zip:			
Drug	Name (select from list of drugs shown)			
Retacri	it Procrit Epogen			
Quanti	ty: Frequency: Strength:			
Route	of Administration: Expected Length of Therapy:			_
Diagno	osis: ICD Code:			
	ents:			
Pleas	e check the appropriate answer for each applicable question.			
1.	What is the patient's diagnosis?			
	Anemia due to chronic kidney disease (CKD) (If checked, go to 2)			
	Anemia due to myelosuppressive chemotherapy (If checked, go to 2)			
	Anemia in myelodysplastic syndrome (MDS) (If checked, go to 2)			
	Presurgical use to reduce allogeneic blood transfusions (If checked, go to 31)			
	Anemia in rheumatoid arthritis (If checked, go to 2)			
	Anemia due to hepatitis C treatment (If checked, go to 2)			
	Anemia due to zidovudine treatment in a patient with HIV infection (If checked, go to 2)			
	Anemia in patients whose religious beliefs forbid blood transfusions (If checked, go to 2)			
	Anemia in primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (If checked, go to 2)			
	Anemia due to cancer (If checked, go to 2)			
	Other, please specify. (If checked, no further questions)			
2.	Will the requested medication be used concomitantly with other erythropoiesis stimulating agents (ESAs)?	Y	N	
3.	Has the patient received erythropoiesis stimulating agent (ESA) therapy in the previous month (within 30 days of request)?	Y	N	

4.	Has the patient completed at least 12 weeks of erythropoiesis stimulating agent (ESA) therapy? Indicate therapy start date and number of weeks completed.	Y	N	
5.	At any time since the patient started ESA therapy, has the patient's hemoglobin (Hgb) increased by 1 g/dL or more?	Y	N	
6.	At any time since the patient started ESA therapy, has the patient's hemoglobin (Hgb) increased by 1 g/dL or more?	Y	N	
7.	Has the patient been assessed for iron deficiency anemia?	Υ	N	
8.	What is the most recent serum transferrin saturation (TSAT) level? Indicate percentage.			
	Less than 20% (If checked, go to 10)			
	Greater than or equal to 20% (If checked, go to 9)		 	
	Unknown (If checked, go to 10)			
9.	Was the most recent serum transferrin saturation (TSAT) level obtained within the prior 3 months? Indicate date lab was drawn.	Y	N	
10.	Is the patient receiving iron therapy?	Υ	N	
11.	What is the patient's diagnosis?			
	Anemia due to chronic kidney disease (CKD) (If checked, go to 15)			
	Anemia due to myelosuppressive chemotherapy (If checked, go to 12)			
	Anemia in myelodysplastic syndrome (MDS) (If checked, go to 15)			
	Anemia in rheumatoid arthritis (If checked, go to 15)			
	Anemia due to hepatitis C treatment (If checked, go to 13)			
	Anemia in patients whose religious beliefs forbid blood transfusions (If checked, go to 15)			
	Anemia due to zidovudine treatment in a patient with HIV infection (If checked, go to 14)			
	Anemia in primary myelofibrosis, post-polycythemia vera myelofibrosis, or post essential thrombocythemia myelofibrosis (If checked, go to 15)			
	Anemia due to cancer (If checked, go to 17)			
12.	Does the patient have a non-myeloid malignancy?	Υ	N	
13.	Is the patient currently receiving treatment with ribavirin in combination with either interferon alfa or peginterferon alfa?	Y	N	
14.	Is the patient currently receiving a zidovudine-containing medication?	Υ	N	
15.	What is the patient's current hemoglobin (Hgb) level (exclude values due to a recent transfusion)?			
	Less than 12 g/dL (If checked, go to 16)			
	Greater than or equal to12 g/dL (If checked, no further questions)			
	Unknown (If checked, no further questions)			
16.	Was the patient's current hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.			
	Yes (If checked, no further questions)			
	No (If checked, no further questions)			
	Unknown (If checked, no further questions)			
17.	Is the patient undergoing palliative treatment?	Υ	N	
18.	Has the patient been assessed for iron deficiency anemia?	Y	N	
19.	What is the most recent serum transferrin saturation (TSAT) level? Indicate percentage.	-	 	
	Less than 20 % (If checked, go to 21)			

	Greater than or equal to 20% (If checked, go to 20)		 	
	Unknown (If checked, go to 21)			
20.	Was the most recent serum transferrin saturation (TSAT) level obtained within the prior 3 months? Indicate date lab was drawn.	Y	N	
21.	Is the patient receiving iron therapy?	Υ	N	
22.	What is the patient's diagnosis?			
	Anemia in chronic kidney disease (CKD) (If checked, go to 28)			
	Anemia due to myelosuppressive chemotherapy (If checked, go to 23)			
	Anemia in myelodysplastic syndrome (MDS) (If checked, go to 28)			
	Anemia in rheumatoid arthritis (If checked, go to 28)			
	Anemia due to hepatitis C treatment (If checked, go to 27)			
	Anemia due to zidovudine treatment in a patient with HIV infection (If checked, go to 24)			
	Anemia in patients whose religious beliefs forbid blood transfusions (If checked, go to 28)			
	Anemia in primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis (If checked, go to 26)			
	Anemia due to cancer (If checked, go to 30)			
23.	Does the patient have a non-myeloid malignancy?	Υ	N	
24.	Is the patient currently receiving treatment with a zidovudine-containing medication?	Υ	N	
25.	What is the patient's pretreatment serum erythropoietin (EPO) level?			
	Less than or equal to 500 mU/mL (If checked, go to 28)			
	Greater than 500 mU/mL (If checked, no further questions)			
	Unknown (If checked, no further questions)			
26.	What is the patient's pretreatment serum erythropoietin (EPO) level?			
	Less than 500 mU/mL (If checked, go to 28)			
	Greater than or equal to 500 mU/mL (If checked, no further questions)			
	Unknown (If checked, no further questions)			
27.	Is the patient currently receiving treatment with ribavirin in combination with either interferon alfa or peginterferon alfa?	Y	N	
28.	What is the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion)?			
	Less than 10 g/dL (If checked, go to 29)			
	Greater than or equal to 10 g/dL (If checked, no further questions)			
	Unknown (If checked, no further questions)			
29.	Was the patient's pretreatment hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.	Y	N	
30.	Is the patient undergoing palliative treatment?	Υ	N	
31.	Will the requested drug be used concomitantly with other erythropoiesis stimulating agents (ESAs)?	Y	N	
32.	Has the patient been assessed for iron deficiency anemia?	Υ	N	
33.	What is the most recent serum transferrin saturation (TSAT) level? Indicate percentage.			
	Less than 20% (If checked, go to 35)			
	Greater than or equal to 20% (If checked, go to 34)			

	Unknown (If checked, go to 35)		
34.	Was the most recent serum transferrin saturation (TSAT) level obtained within the prior 3 months? Indicate date lab was drawn.	Y	N 🗆
35.	Is the patient receiving iron therapy?	Y	N 🗆
36.	Is the patient scheduled to have an elective, noncardiac, nonvascular surgery?	Υ	N
37.	What is the patient's pretreatment hemoglobin (Hgb) level (exclude values due to a recent transfusion)?		
	Less than or equal to 13g/dL (If checked, go to 38)		
	Greater than 13g/dL (If checked, no further questions)		
	Unknown (If checked, no further questions)		
38.	Was the patient's pretreatment hemoglobin (Hgb) level drawn within 30 days of the request (exclude values due to a recent transfusion)? Indicate date lab was drawn.		
	Yes (If checked, no further questions)		
	No (If checked, no further questions)		
	Unknown (If checked, no further questions)		
accu	st that the medication requested is medically necessary for this patient. I further attest that rate and true, and that the documentation supporting this information is available for reviewessor, the health plan sponsor, or, if applicable a state or federal regulatory agency.		

Prescriber (Or Authorized) Signature and Date
Now you can get responses to drug PAs immediately and securely online—without faxes, phone calls, or waiting. How? With electronic prior authorization (ePA)! For more information and to register, go to www.caremark.com/epa.